Viralytics Ltd (VLA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Viralytics Ltd (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013495
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Viralytics Ltd (Viralytics), formerly Psiron Ltd is a provider of development and commercialisation of oncolytic immunotherapies. The company develops oncolytic immunotherapies for the treatment of different types of cancers. It offers cavataktm, a proprietary formulation for the common cold Coxsackievirus Type A21. Viralytics’ cavataktm is an oncolytic common cold virus that has demonstrated anti-tumor activity, by following a process called lysis. The company’s products are evaluated both as an intratumoural and intravenous agent in melanoma, prostate, lung and bladder cancers. It conducts research and development through medical research institutes and research facilities in Newcastle. Viralytics is headquartered in Sydney, New South Wales, Australia.

Viralytics Ltd (VLA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Viralytics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Viralytics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Viralytics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Viralytics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Viralytics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Viralytics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Viralytics Enters into Agreement with Merck 10
Viralytics Enters into Partnership with University of Surrey 11
Equity Offering 12
Viralytics Raises USD3 Million in Share Purchase Plan 12
Viralytics Raises USD20.8 Million in Private Placement of Shares 14
Viralytics Completes Second Tranche Of Private Placement Of Shares For US$20.2Million 16
Viralytics Completes Rights Offering Of Shares For US$3.6 Million 18
Viralytics Ltd – Key Competitors 19
Viralytics Ltd – Key Employees 20
Viralytics Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 18, 2017: Viralytics Annual Report and Full Year Financial Results 22
Product News 24
11/22/2016: Viralytics Announces Formation of Clinical Advisory Board 24
03/15/2016: Positive CAVATAK Clinical Data Presented at 2016 European Association of Urology Congress 25
Clinical Trials 26
Apr 05, 2017: Viralytics moves into the Expansion Phase and Reports on Progress in the CAVATAK and KEYTRUDA Combination KEYNOTE-200 clinical trial at AACR Conference 26
Apr 05, 2017: Viralytics’ CAVATAK in Combination with YERVOY Provides Promising Results in Advanced Melanoma from the Phase 1b MITCI clinical study 27
Mar 02, 2017: Viralytics to Present New CAVATAK Clinical Data at American Association for Cancer Research Annual Meeting 2017 29
Oct 04, 2016: Viralytics Presents CAVATAK Trial Results at Oncolytic Virus Therapeutics Conference 31
Jun 06, 2016: Updated clinical trial data on CAVATAK tumour targeting and immune-activation presented at the American Society Clinical Oncology Annual Meeting 33
Apr 19, 2016: Positive Clinical Data from CAVATAK and YERVOY Combination presented at the 2016 AACR Annual Meeting 35
Apr 18, 2016: Further Promising CAVATAK Trial Data to be presented at Association for Cancer Research Annual Meeting 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Viralytics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Viralytics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Viralytics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Viralytics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Viralytics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Viralytics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Viralytics Enters into Agreement with Merck 10
Viralytics Enters into Partnership with University of Surrey 11
Viralytics Raises USD3 Million in Share Purchase Plan 12
Viralytics Raises USD20.8 Million in Private Placement of Shares 14
Viralytics Completes Second Tranche Of Private Placement Of Shares For US$20.2Million 16
Viralytics Completes Rights Offering Of Shares For US$3.6 Million 18
Viralytics Ltd, Key Competitors 19
Viralytics Ltd, Key Employees 20
Viralytics Ltd, Other Locations 21

★海外企業調査レポート[Viralytics Ltd (VLA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Vanguard Group, Inc.:企業の戦略・SWOT・財務情報
    The Vanguard Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Vanguard Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Atlantic Airways P/F:企業の戦略・SWOT・財務情報
    Atlantic Airways P/F - Strategy, SWOT and Corporate Finance Report Summary Atlantic Airways P/F - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Jazz Pharmaceuticals Plc (JAZZ)-製薬・医療分野:企業M&A・提携分析
    Summary Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment o …
  • Marshall Aerospace and Defence Group:企業の戦略・SWOT・財務情報
    Marshall Aerospace and Defence Group - Strategy, SWOT and Corporate Finance Report Summary Marshall Aerospace and Defence Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Galen Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Galen Ltd (Galen), a subsidiary of Almac Group Ltd, is a pharmaceutical company. The company’s products include trustsaver, calceos, salivix, daunoxome, flotros, histofreezer, laxido, and saline steripoules, among others. It offers products in various therapy areas including angina, constipa …
  • Lea County Electric Cooperative Inc:企業の戦略的SWOT分析
    Lea County Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Wm Morrison Supermarkets PLC:企業のM&A・事業提携・投資動向
    Wm Morrison Supermarkets PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wm Morrison Supermarkets PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • S.C. Termoelectrica SA:企業の戦略的SWOT分析
    S.C. Termoelectrica SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Tecnicas Reunidas SA (TRE):企業の財務・戦略的SWOT分析
    Tecnicas Reunidas SA (TRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Devon Energy Corporation:企業の戦略・SWOT・財務分析
    Devon Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Devon Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Recordati SpA (REC):製薬・医療:M&Aディール及び事業提携情報
    Summary Recordati SpA (Recordati), a subsidiary of Fimei SpA is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, dermatology, central nervous system disorders, musculo-skeletal disorders and …
  • Actelion Ltd:戦略・SWOT・企業財務分析
    Actelion Ltd - Strategy, SWOT and Corporate Finance Report Summary Actelion Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • NanoString Technologies Inc (NSTG):企業の財務・戦略的SWOT分析
    Summary NanoString Technologies Inc (NanoString) is a developer of life science tools for translational research and molecular diagnostics. The company's products include sprint profiler, Dx analysis system with flex, nCounter MAX analysis system, protein assays, solid tumor assays, gene fusion pane …
  • Astellas Pharma Inc.:企業の戦略・SWOT・財務分析
    Astellas Pharma Inc. - Strategy, SWOT and Corporate Finance Report Summary Astellas Pharma Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ipsen Biopharmaceuticals Inc:企業の戦略的SWOT分析
    Ipsen Biopharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Marks and Spencer Group plc:企業の戦略・SWOT・財務情報
    Marks and Spencer Group plc - Strategy, SWOT and Corporate Finance Report Summary Marks and Spencer Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Arvind Ltd:企業の戦略・SWOT・財務情報
    Arvind Ltd - Strategy, SWOT and Corporate Finance Report Summary Arvind Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • West Cornwall Pasty Co. Ltd:企業の戦略・SWOT・財務分析
    West Cornwall Pasty Co. Ltd - Strategy, SWOT and Corporate Finance Report Summary West Cornwall Pasty Co. Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Furukawa Electric Co., Ltd.:企業の戦略・SWOT・財務情報
    Furukawa Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Furukawa Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Bassett Furniture Industries, Incorporated (BSET):企業の財務・戦略的SWOT分析
    Bassett Furniture Industries, Incorporated (BSET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆